news
EC approves label update for Pfizer’s Xalkori in NSCLC
26 November 2015 | By Victoria White
The EC has approved a label update to expand the use of Xalkori (crizotinib) to first-line treatment of adults with ALK-positive NSCLC...
List view / Grid view
Lung cancer
news
FDA approves Portrazza for metastatic squamous NSCLC
25 November 2015 | By Victoria White
The approval is based on the Phase III study where the Portrazza regimen demonstrated a significant improvement in overall survival...
news
Phase III study to evaluate pemetrexed and pembrolizumab in NSCLC
19 November 2015 | By Victoria White
Lilly and Merck are to evaluate the safety and efficacy of the combination of pemetrexed and pembrolizumab in a Phase III study in non-squamous NSCLC...
news
Pfizer’s Phase 3 Xalkori NSCLC trial meets primary objective
18 November 2015 | By Victoria White
Xalkori demonstrated significantly prolonged progression-free survival in previously untreated East Asian patients with ALK-positive advanced NSCLC...
news
Global NSCLC treatment market value to rise to $10.9 billion
17 November 2015 | By Victoria White
GBI Research says that the introduction of novel immune-checkpoint inhibitors, such as Opdivo and Keytruda, will drive the market...
news
FDA approves Tagrisso for non-small cell lung cancer
13 November 2015 | By Victoria White
Tagrisso (AZD9291) is the only approved medicine indicated for patients with metastatic EGFR T790M mutation-positive non-small cell lung cancer...
news
Boehringer Ingelheim initiates Phase II trial of BI 1482694 in NSCLC
3 November 2015 | By Victoria White
BI 1482694 is a novel, third-generation, oral, irreversible EGFR mutant-specific tyrosine kinase inhibitor (TKI) developed to specifically target tumours with T790M mutations...
news
Keytruda demonstrates superior overall survival to chemotherapy in NSCLC study
26 October 2015 | By Victoria White
The Phase 2/3 KEYNOTE-010 trial compared two doses of Keytruda to docetaxel...
news
FDA approves Opdivo for metastatic non-squamous NSCLC
12 October 2015 | By Victoria White
In a Phase 3 trial, Opdivo demonstrated superior overall survival (OS) in previously treated metastatic non-squamous NSCLC compared to chemotherapy...
news
FDA approves Keytruda for patients with metastatic NSCLC
5 October 2015 | By Victoria White
Keytruda is now the first and only anti-PD-1 ((programmed death receptor-1) therapy approved for both squamous and non-squamous metastatic NSCLC...
news
Further evidence for the potential of AZD9291 in NSCLC presented at WCLC
9 September 2015 | By Victoria White
Data demonstrated that in 60 patients who received AZD9291 once daily in the first-line setting, 72% were progression free at 12 months...
news
NSCLC treatment market value to approach $11 billion by 2021
8 September 2015 | By Victoria White
This increase will be driven primarily by the introduction of novel immune-checkpoint inhibitors, such as Opdivo and Keytruda, says GBI Research...
news
Opdivo demonstrates sustained survival results in squamous NSCLC
8 September 2015 | By Victoria White
In two studies, Opdivo showed an estimated 18 month overall survival rate of 27% to 28% in patients with previously treated squamous non-small cell lung cancer (NSCLC)...
news
Atezolizumab shrank tumours in people with NSCLC in PII study
17 August 2015 | By Victoria White
In Roche’s large pivotal Phase II study, BIRCH, atezolizumab met its primary endpoint and shrank tumours in people with locally advanced or metastatic NSCLC...
news
EMA validates two Opdivo indication extension applications
23 July 2015 | By Victoria White
The EMA has validated two type II variation applications which seek to extend the indication of Opdivo in non-squamous NSCLC and advanced melanoma...
